Apontis Pharma AG
XETRA:APPH
Apontis Pharma AG
Retained Earnings
Apontis Pharma AG
Retained Earnings Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Retained Earnings | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
A
|
Apontis Pharma AG
XETRA:APPH
|
Retained Earnings
€21.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
ATAI Life Sciences NV
NASDAQ:ATAI
|
Retained Earnings
-$550.9m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Bayer AG
XETRA:BAYN
|
Retained Earnings
€11.1B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-1%
|
|
![]() |
Merck KGaA
XETRA:MRK
|
Retained Earnings
€29.3B
|
CAGR 3-Years
21%
|
CAGR 5-Years
17%
|
CAGR 10-Years
11%
|
|
![]() |
Dermapharm Holding SE
XETRA:DMP
|
Retained Earnings
€429.1m
|
CAGR 3-Years
17%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
![]() |
PharmaSGP Holding SE
XETRA:PSG
|
Retained Earnings
-€10.8m
|
CAGR 3-Years
35%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Apontis Pharma AG
Glance View
APONTIS PHARMA AG engages in the development, promotion, and sale of single pills and other pharmaceutical products. The company is headquartered in Monheim Am Rhein, Nordrhein-Westfalen and currently employs 176 full-time employees. The company went IPO on 2021-05-11. The firm focuses on the commercialization of pharmaceutical products to General Practitioners and engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany.
See Also
What is Apontis Pharma AG's Retained Earnings?
Retained Earnings
21.9m
EUR
Based on the financial report for Dec 31, 2023, Apontis Pharma AG's Retained Earnings amounts to 21.9m EUR.
What is Apontis Pharma AG's Retained Earnings growth rate?
Retained Earnings CAGR 1Y
-34%
Over the last year, the Retained Earnings growth was -34%.